Since blockade of PD- 1/PD-L1 has shown limited ability to treat some of the tumours, ongoing clinical trials are mostly using PD-1/PD-L1 blocking mAbs with other myeloid targets covered in this review. This evidence concerns the gene RPL17 and neoplasm.